Thiazolidinediones have been introduced in the treatment of type 2 diabetes mellitus
(T2DM) since the late 1990s. Although troglitazone was withdrawn from the market a few …

Guidelines have increasingly stressed the concept that adequate glycemic control is
required to prevent or decrease the macro-and microvascular complications of type 2 …

Type 2 diabetes mellitus is characterised by insulin resistance as well as progressive
pancreatic β cell dysfunction. The cornerstone of current oral blood-glucose lowering …

Introduction: Thiazolidinediones (TZDs) initially showed great promise as unique receptor-
mediated oral therapy for type 2 diabetes, but a host of serious side effects, primarily …

The thiazolidinediones (TZDs) or 'glitazones' are a new class of drug used for the treatment
of type 2 diabetes. Although their precise mechanism of action is not known, TZDs target …

The thiazolidinediones, rosiglitazone and pioglitazone are used in the treatment of Type 2
diabetes (T2DM). Both have been shown to decrease glycated haemoglobin levels, fasting …

Among the epidemics of modern time, type 2 diabetes mellitus (T2DM) is one of the main
contributors to overall morbidity as well as mortality. A number of different treatment options …

Thiazolidinediones (TZD), or glitazones, represent a new generation of antidiabetic drugs
that have recently been introduced in Europe. They improve insulin resistance, one of the …

Thiazolidinediones (TZDs) form a new class of oral antidiabetic agents. They improve insulin
sensitivity and reduce glycemia, lipidemia and insulinemia in patients with type 2 diabetes …

Thiazolidinediones (TZDs) are insulin-sensitizing antidiabetes agents that act through the
peroxisome proliferator–activated receptor-γ to cause a durable improvement in glycemic …